Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Therapieën in combinatie of opeenvolgend met tyrosinekinaseremmers (TKI's) bij patiënten met chronische myeloïde leukemie in de chronische fase in CCR (ACTIW) (ACTIW)

25 september 2026 bijgewerkt door: Philippe ROUSSELOT, Versailles Hospital

Kandidaat-therapieën in combinatie of opeenvolgend met tyrosinekinaseremmers bij patiënten met chronische fase-chronische myeloïde leukemie in CCR zonder een diepe moleculaire respons te bereiken: een adaptieve studie op basis van een Drop Loser-ontwerp

Patients will be randomized in phase II trials to continue on the same TKI versus one of the alternative treatment approaches. If a patient is not eligible for one of the treatments, he (she) will be randomized between the options for which he (she) is eligible.

The trial will start with current available treatment options (experimental arms). New available treatment options may be open at any times later on. Authorized TKIs are imatinib, nilotinib, dasatinib, bosutinib and ponatinib.

For all options the treatment duration is for a minimum of 12 months and will be continued in the absence of adverse events following investigator decision. Each therapeutic option will be detailed in term of combination modalities, dose, dose adaptation, specific warnings, specific exclusion and inclusion criteria. The decision to introduce a new option will depend on the general pace of recruitment and on the assessment of the potential efficacy and safety of the new treatment, and will be implemented after scientific review by a protocol amendment.

Primary objective:

A. To select molecules in combination or sequentially with imatinib, nilotinib, dasatinib, bosutinib or ponatinib potentially able to produce a 25% increase in the Cumulative Incidence of MR4.5 as compare to control.

Secondary objectives:

A. To determine the safety of selected therapies

B. To determine the rate of MR4 by 12, 24, 36, 48 months in experimental and control arms

C. To determine the rates of MR4.5 by 24, 36, 48 months in experimental and control arms

D. To determine the rate of undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12, 24, 36, 48 months in experimental and control arms

E. To estimate treatment free remission (TFR) in patients eligible for discontinuation studies

F. To investigate the relationship between biological activity and the clinical efficacy of the selected therapies

G. To assess the effects of the treatments on the number and clonogenicity of CML stem cells and other biological markers of interest

H. To estimate duration of response, progression-free survival, event free survival and overall survival.

Studie Overzicht

Toestand

Actief, niet wervend

Gedetailleerde beschrijving

Patients will be randomised to continue on TKI (same daily dose) versus one of the alternative novel treatment approaches. If a patient is not eligible for one of the treatments, he can be randomised for the options for which he is eligible. All treatment options may be open at all times. Investigators must specify before randomization for which treatment option they want their patient be included and randomized.

Perspectives New treatment options will be introduced over time. The decision to introduce a new option will depend on the general pace of recruitment and the assessment of the potential efficacy and safety of the new treatment in this patient population, and will be implemented after scientific review by a protocol amendment.

The available treatment arms are:

  1. TKI alone same daily dose (control arm)
  2. TKI in combination with pioglitazone
  3. TKI in combination with Avelumab (anti-PD-L1 antibody)

Planned treatment arms for the future may be :

  1. TKI in combination with pegylated interferon
  2. TKI in combination with arsenic trioxide
  3. TKI in combination with Homoharringtonine

Protocol plan:

  1. Control arm (Imatinib, nilotinib, dasatinib, bosutinib or ponatinib):

    Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

  2. Pioglitazone arm

    • TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

    • PIOGLITAZONE (Actos®):

      30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.

    • After 12 Months :

    Continue TKI at the same daily dose and STOP pioglitazone.

  3. AVELUMAB arm

    • TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
    • AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
    • After 12 Months :Continue TKI at the same daily dose.
  4. Other experimental arm TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

    • Arsenic trioxide : to be determined after amendment
    • Pegylated Interferon : to be determined after amendment
    • Homoharringtonine : to be determined after amendment
    • Drug X
    • Drug Y

Studietype

Ingrijpend

Inschrijving (Geschat)

100

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Angers, Frankrijk
        • Martine GARDEMBAS
      • Annecy, Frankrijk
        • Pascale CONY.MAKHOUL
      • Bobigny, Frankrijk
        • Thorsten BRAUN
      • Bordeaux, Frankrijk
        • Etienne
      • Caen, Frankrijk
        • CHU Côte de Nacre
      • Clermont-Ferrand, Frankrijk
        • CHU Estaing
      • Créteil, Frankrijk
        • CH Henri Mondor
      • Le Chesnay, Frankrijk
        • Rousselot
      • Lille, Frankrijk
        • CHU Lille
      • Limoges, Frankrijk
        • CHU de LIMOGES
      • Lyon, Frankrijk
        • Franck NICOLINI
      • Marseille, Frankrijk
        • Institut P Calmette
      • Nantes, Frankrijk
        • Viviane DUBRUILLE
      • Nice, Frankrijk
        • Hopital l'Archet
      • Nîmes, Frankrijk
        • Eric JOURDAN
      • Orléans, Frankrijk
        • Hôpital La Source
      • Paris, Frankrijk
        • Delphine REA _St louis
      • Paris, Frankrijk
        • Simona LAPUSAN_St Antoine
      • Poitiers, Frankrijk
        • Cayssials
      • Rennes, Frankrijk
        • CHU de Rennes - Pontchaillou
      • Saint-Cloud, Frankrijk
        • Hôpital René Huguenin
      • Toulouse, Frankrijk
        • Institut Universitaire contre le Cancer
      • Tours, Frankrijk
        • CHU Tours

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Common Inclusion Criteria:

  1. Patient aged 18y or more
  2. Signed informed consent
  3. Patient with Philadelphia chromosome positive chronic phase CML and M BCR-ABL1 transcript positivity at diagnosis
  4. Treatment with imatinib, nilotinib, dasatinib or bosutinib for more than 2 years overall
  5. No switch between tyrosine kinase inhibitors within the last 3 months
  6. No dose modification within the last 3 months
  7. Complete cytogenetic response or BCR-ABL1IS ≤ 1%
  8. Detectable BCR-ABL1 with BCR-ABL1IS > 0.0032% (less than MR4.5)
  9. ECOG grade 0 to 2
  10. ASAT and ALAT ≤ 2.5 N
  11. Bilirubin in serum ≤ 2.5 N
  12. Men and Women of childbearing potential must be using an adequate method of contraception

These specific inclusion criteria will apply for the Avelumab arm in addition to the common criteria.

  1. Hematologic:

    1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L,
    2. Platelet count ≥ 100 × 109/L,
    3. Hemoglobin ≥ 9 g/dL. (may have been transfused).
  2. Hepatic:

    a. Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range.

  3. Renal: Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)

  4. Pregnancy test: Negative serum or urine pregnancy test at screening for women of childbearing potential.

  5. Contraception: Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last Avelumab treatment administration if the risk of conception exists.

Common Exclusion Criteria:

  1. Pregnant or lactating women,

  2. Participation in another clinical trial with any investigative drug within 30 days prior to study enrolment,

  3. Prior history of hematopoietic stem cell transplantation (autologous or allogenic)

  4. Cardiovascular disease:

    • Stage II to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system for heart failure.
    • Myocardial infarction within the previous 6 months
    • Symptomatic cardiac arrhythmia requiring treatment
  5. Grade III or IV fluid retention

  6. Known BCR-ABL kinase domain mutation

  7. CML patient not in chronic phase at diagnosis

  8. Individuals with an active malignancy

  9. Known HIV-positivity

These specific exclusion criteria will apply for the pioglitazone arm in addition to the common criteria.

  1. Known osteoporosis with curative therapy (prophylactic therapy is not an exclusion criteria)
  2. Patient requiring anti-diabetic medication

These specific exclusion criteria will apply for the Avelumab arm in addition to the common criteria:

  1. IMMUNOSUPRESSANTS: Current use of immunosuppressive medication, EXCEPT for the following:

    1. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection);
    2. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent;
    3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
  2. AUTOIMMUNE DISEASE: Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.

  3. ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell transplantation.

  4. INFECTIONS: Active infection requiring systemic therapy.

  5. HIV/AIDS: Known history of testing positive for HIV or known acquired immunodeficiency syndrome.

  6. HEPATITIS: Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)

  7. VACCINATION: Vaccination within 4 weeks of the first dose of Avelumab and while on trials is prohibited except for administration of inactivated vaccines

  8. HYPERSENSITIIVTY TO STUDY DRUG: Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions tomonoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3)

  9. CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia equiring medication.

  10. OTHER PERSISTING TOXICITIES: Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.

  11. Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Experimental Arm_ACTOS

TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

PIOGLITAZONE (Actos®):

30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.

PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.

Geen tussenkomst: controled Arm

TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

Experimenteel: Experimental Arm_AVELUMAB

TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period.(If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)

10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cumulative incidence of patients achieving a deep molecular response
Tijdsspanne: 12 months

The cumulative incidence of patients achieving a deep molecular response defined by MR4.5 or deeper (BCR-ABLIS ≤ 0.0032 %) by 12 months

12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Kwantificering van CML- en normale CFU in beenmerg door middel van klonogene assays en RTQ-PCR
Tijdsspanne: 12 maanden
12 maanden
Adverse events
Tijdsspanne: 12 Months

Adverse events

12 Months
The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms
Tijdsspanne: 24 months

The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms

24 months
The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms
Tijdsspanne: 36 months

The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms

36 months
The cumulative rate of patients achieving MR4.5 by 48 months in experimental and control arms
Tijdsspanne: 48 months

The cumulative rate of patients achieving MR4.5 by 48months in experimental and control arms

48 months
The cumulative rate of patients achieving MR4 by 12months in experimental and control arms
Tijdsspanne: 12 months

The cumulative rate of patients achieving MR4 by 12,months in experimental and control arms

12 months
The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms
Tijdsspanne: 24 months

The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms

24 months
The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms
Tijdsspanne: 36 months

The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms

36 months
The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms
Tijdsspanne: 48 months

The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms

48 months
The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms
Tijdsspanne: 12 months

The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms

12 months
The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24months in experimental and control arms
Tijdsspanne: 24 months

The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24, months in experimental and control arms

24 months
The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms
Tijdsspanne: 36 months

The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms

36 months
The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms
Tijdsspanne: 48 months

The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms

48 months
The rate of patients in treatment free remission during follow-up
Tijdsspanne: 48 months

The rate of patients in treatment free remission during follow-up

48 months
Survival
Tijdsspanne: 48 months

Survival

48 months
duration of response
Tijdsspanne: 48 months

duration of response

48 months
event free survival
Tijdsspanne: 48 months

event free survival

48 months
progression free survival
Tijdsspanne: 48 months

progression free survival

48 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Philippe ROUSSELOT, CH Versailles

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 juli 2016

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 juni 2028

Studieregistratiedata

Eerst ingediend

16 maart 2016

Eerst ingediend dat voldeed aan de QC-criteria

6 mei 2016

Eerst geplaatst (Geschat)

10 mei 2016

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 september 2026

Laatste update ingediend die voldeed aan QC-criteria

25 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren